Cognition Therapeutics (NASDAQ:CGTX) Research Coverage Started at Chardan Capital

Chardan Capital assumed coverage on shares of Cognition Therapeutics (NASDAQ:CGTXFree Report) in a research note issued to investors on Thursday, Benzinga reports. The brokerage issued a buy rating and a $11.00 price objective on the stock.

Several other brokerages also recently issued reports on CGTX. HC Wainwright began coverage on shares of Cognition Therapeutics in a research note on Wednesday, May 29th. They issued a buy rating and a $10.00 target price for the company. B. Riley reaffirmed a buy rating and issued a $5.00 price objective on shares of Cognition Therapeutics in a research report on Thursday, March 28th. Finally, Oppenheimer reissued an outperform rating and set a $9.00 target price on shares of Cognition Therapeutics in a report on Wednesday, March 27th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Cognition Therapeutics currently has an average rating of Buy and an average target price of $8.20.

View Our Latest Research Report on CGTX

Cognition Therapeutics Stock Down 3.7 %

CGTX stock opened at $1.83 on Thursday. The company has a market cap of $73.31 million, a price-to-earnings ratio of -1.99 and a beta of 1.53. Cognition Therapeutics has a twelve month low of $0.90 and a twelve month high of $3.49. The business has a 50 day moving average price of $2.01 and a two-hundred day moving average price of $1.93.

Cognition Therapeutics (NASDAQ:CGTXGet Free Report) last issued its earnings results on Tuesday, May 7th. The company reported ($0.27) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.04). On average, equities research analysts anticipate that Cognition Therapeutics will post -0.98 EPS for the current fiscal year.

Institutional Trading of Cognition Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Sigma Planning Corp acquired a new stake in shares of Cognition Therapeutics in the fourth quarter valued at approximately $53,000. Texas Capital Bank Wealth Management Services Inc bought a new position in Cognition Therapeutics during the 4th quarter worth $102,000. Twin Focus Capital Partners LLC acquired a new position in Cognition Therapeutics in the 4th quarter valued at $173,000. Hohimer Wealth Management LLC bought a new stake in shares of Cognition Therapeutics during the 1st quarter valued at $410,000. Finally, Tocqueville Asset Management L.P. acquired a new stake in shares of Cognition Therapeutics during the 1st quarter worth $47,000. Institutional investors and hedge funds own 43.35% of the company’s stock.

Cognition Therapeutics Company Profile

(Get Free Report)

Cognition Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies.

Featured Articles

Analyst Recommendations for Cognition Therapeutics (NASDAQ:CGTX)

Receive News & Ratings for Cognition Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cognition Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.